Background Oxaliplatin is a chemotherapy agent active against digestive tumors. Peripheral
neuropathy is one of the most important dose-limiting toxicity of this drug. It occurs in around …

Aim: It was the aim of this study to test the hypothesis that the voltage-gated sodium channel
gene SCN2A R19K polymorphism confers liability to oxaliplatin-induced peripheral …

BACKGROUND The current prospective, multicenter study sought to identify single
nucleotide polymorphisms of voltage‐gated sodium channels (SCNAs) genes that might …

Oxaliplatin is a platinum drug active against digestive tract cancers. Among its side effects,
peripheral neuropathy is one of the dose-limiting toxicities. This affects around 50 to 70% of …

Background Sodium channels located in the dorsal root ganglion, particularly Nav1. 7 and
Nav1. 8, encoded by SCN9A and SCN10A, respectively, act as molecular gatekeepers for …

Simple Summary Chemotherapy-induced peripheral neuropathy (CIPN) is a common
debilitating complication of treatment with platinum-based compounds and taxanes. CIPN is …

Purpose There is no agreement on which channel is involved in oxaliplatin neurotoxicity,
most investigators favouring voltage-gated sodium channels. However, the small …

Oxaliplatin-induced peripheral neurotoxicity (OXPN) is a dose-limiting toxicity in colorectal
cancer (CRC) patients. Single nucleotide polymorphisms (SNPs) in genes involved in drug …

Background Peripheral sensory neuropathy (PSN) is a dose-limiting toxicity of oxaliplatin-
based chemotherapy. Several genetic markers have been shown to predict oxaliplatin …

The manuscript by Park et al. in this issue of Annals of Oncology [1] reports on potential
clinical and genetic prognostic factors of chemotherapy-induced peripheral neuropathy …